This use of once-daily Reyataz boosted with ritonavir (Reyataz/r) in HIV-1 infected treatment-naive adult patients is based on 48-week results from the Castle study, which demonstrated similar antiviral efficacy of Reyataz/r to twice-daily lopinavir/ritonavir, each as part of HIV combination therapy, in treatment-naive HIV-1 infected adult patients.
Reyataz/r taken once daily with food is recognized by the US Department of Health and Human Services (DHHS) as a preferred component of combination HIV therapy for treatment-naive patients. For treatment-naive patients who are unable to tolerate ritonavir, Reyataz 400mg (without ritonavir), taken once daily with food, is recommended.
Elliott Sigal, executive vice president, chief scientific officer and president of R&D at Bristol-Myers Squibb, said: “Bristol-Myers Squibb is committed to developing medicines that enhance the care of people living with HIV and AIDS. Boosted Reyataz provides healthcare professionals a newly approved, once-daily dosing option as part of combination therapy for patients naive to HIV therapy.”